Antimicrobial Resistance in Gram-Negative Bacterial Pneumonia After the COVID-19 Pandemic in Northern Iran

Background: The irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked to an increasing burden of healthcare-associated infections caused by multidrug-resistant pathogens, which present substantial challenges for...

Full description

Saved in:
Bibliographic Details
Published inAdvanced biomedical research Vol. 14; no. 1; p. 92
Main Authors Rahimzadeh, Golnar, Askari, Mahdieh, Rezai, Raha, Rezai, Shaghayegh, Rezai, Mohammad Sadegh, Moradi, Masoud
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer - Medknow 01.08.2025
Medknow Publications and Media Pvt. Ltd
Medknow Publications & Media Pvt. Ltd
Wolters Kluwer Medknow Publications
Edition2
Subjects
Online AccessGet full text
ISSN2277-9175
2277-9175
DOI10.4103/abr.abr_262_25

Cover

Abstract Background: The irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked to an increasing burden of healthcare-associated infections caused by multidrug-resistant pathogens, which present substantial challenges for infection control and patient management. During the COVID-19 pandemic, the widespread use of antibiotics for treating and preventing secondary bacterial infections further exacerbated the threat of AMR worldwide. This study aimed to determine the antibiotic resistance profile of Gram-negative bacteria (GNB) causing pneumonia after COVID-19 in Northern Iran. Materials and Methods: In this cross-sectional study, respiratory specimens were collected from hospitalized patients with bacterial pneumonia at four hospitals in Northern Iran. The antimicrobial susceptibility profiles were assessed using the standard microdilution method in accordance with CLSI guidelines (2020). Additionally, resistance-associated genetic determinants were evaluated using multiplex PCR. Results: A total of 120 MDR GNB isolates were identified, primarily from sputum specimens (75.8%). Pseudomonas aeruginosa was the most common pathogen in the ICU, representing 35% of isolates. Resistance rates to antibiotics were high: Ciprofloxacin (85%), Ceftazidime (85%), Gentamicin (80%), and Colistin (77.5%), while Piperacillin-Tazobactam had a lower resistance rate of 33.3%. Conclusions: The present study highlights the increasing AMR among GNB causing pneumonia in ICU settings post COVID-19 pandemic in hospitals in Northern Iran. The prevalence of Pseudomonas aeruginosa and high resistance rates to new antibiotics such as Colistin pose significant challenges to treatment, while Piperacillin-Tazobactam shows relatively lower resistance and may be a potential option.
AbstractList Background: The irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked to an increasing burden of healthcare-associated infections caused by multidrug-resistant pathogens, which present substantial challenges for infection control and patient management. During the COVID-19 pandemic, the widespread use of antibiotics for treating and preventing secondary bacterial infections further exacerbated the threat of AMR worldwide. This study aimed to determine the antibiotic resistance profile of Gram-negative bacteria (GNB) causing pneumonia after COVID-19 in Northern Iran. Materials and Methods: In this cross-sectional study, respiratory specimens were collected from hospitalized patients with bacterial pneumonia at four hospitals in Northern Iran. The antimicrobial susceptibility profiles were assessed using the standard microdilution method in accordance with CLSI guidelines (2020). Additionally, resistance-associated genetic determinants were evaluated using multiplex PCR. Results: A total of 120 MDR GNB isolates were identified, primarily from sputum specimens (75.8%). Pseudomonas aeruginosa was the most common pathogen in the ICU, representing 35% of isolates. Resistance rates to antibiotics were high: Ciprofloxacin (85%), Ceftazidime (85%), Gentamicin (80%), and Colistin (77.5%), while Piperacillin-Tazobactam had a lower resistance rate of 33.3%. Conclusions: The present study highlights the increasing AMR among GNB causing pneumonia in ICU settings post COVID-19 pandemic in hospitals in Northern Iran. The prevalence of Pseudomonas aeruginosa and high resistance rates to new antibiotics such as Colistin pose significant challenges to treatment, while Piperacillin-Tazobactam shows relatively lower resistance and may be a potential option.
The irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked to an increasing burden of healthcare-associated infections caused by multidrug-resistant pathogens, which present substantial challenges for infection control and patient management. During the COVID-19 pandemic, the widespread use of antibiotics for treating and preventing secondary bacterial infections further exacerbated the threat of AMR worldwide. This study aimed to determine the antibiotic resistance profile of Gram-negative bacteria (GNB) causing pneumonia after COVID-19 in Northern Iran. In this cross-sectional study, respiratory specimens were collected from hospitalized patients with bacterial pneumonia at four hospitals in Northern Iran. The antimicrobial susceptibility profiles were assessed using the standard microdilution method in accordance with CLSI guidelines (2020). Additionally, resistance-associated genetic determinants were evaluated using multiplex PCR. A total of 120 MDR GNB isolates were identified, primarily from sputum specimens (75.8%). Pseudomonas aeruginosa was the most common pathogen in the ICU, representing 35% of isolates. Resistance rates to antibiotics were high: Ciprofloxacin (85%), Ceftazidime (85%), Gentamicin (80%), and Colistin (77.5%), while Piperacillin-Tazobactam had a lower resistance rate of 33.3%. The present study highlights the increasing AMR among GNB causing pneumonia in ICU settings post COVID-19 pandemic in hospitals in Northern Iran. The prevalence of Pseudomonas aeruginosa and high resistance rates to new antibiotics such as Colistin pose significant challenges to treatment, while Piperacillin-Tazobactam shows relatively lower resistance and may be a potential option.
The irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked to an increasing burden of healthcare-associated infections caused by multidrug-resistant pathogens, which present substantial challenges for infection control and patient management. During the COVID-19 pandemic, the widespread use of antibiotics for treating and preventing secondary bacterial infections further exacerbated the threat of AMR worldwide. This study aimed to determine the antibiotic resistance profile of Gram-negative bacteria (GNB) causing pneumonia after COVID-19 in Northern Iran.BackgroundThe irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked to an increasing burden of healthcare-associated infections caused by multidrug-resistant pathogens, which present substantial challenges for infection control and patient management. During the COVID-19 pandemic, the widespread use of antibiotics for treating and preventing secondary bacterial infections further exacerbated the threat of AMR worldwide. This study aimed to determine the antibiotic resistance profile of Gram-negative bacteria (GNB) causing pneumonia after COVID-19 in Northern Iran.In this cross-sectional study, respiratory specimens were collected from hospitalized patients with bacterial pneumonia at four hospitals in Northern Iran. The antimicrobial susceptibility profiles were assessed using the standard microdilution method in accordance with CLSI guidelines (2020). Additionally, resistance-associated genetic determinants were evaluated using multiplex PCR.Materials and MethodsIn this cross-sectional study, respiratory specimens were collected from hospitalized patients with bacterial pneumonia at four hospitals in Northern Iran. The antimicrobial susceptibility profiles were assessed using the standard microdilution method in accordance with CLSI guidelines (2020). Additionally, resistance-associated genetic determinants were evaluated using multiplex PCR.A total of 120 MDR GNB isolates were identified, primarily from sputum specimens (75.8%). Pseudomonas aeruginosa was the most common pathogen in the ICU, representing 35% of isolates. Resistance rates to antibiotics were high: Ciprofloxacin (85%), Ceftazidime (85%), Gentamicin (80%), and Colistin (77.5%), while Piperacillin-Tazobactam had a lower resistance rate of 33.3%.ResultsA total of 120 MDR GNB isolates were identified, primarily from sputum specimens (75.8%). Pseudomonas aeruginosa was the most common pathogen in the ICU, representing 35% of isolates. Resistance rates to antibiotics were high: Ciprofloxacin (85%), Ceftazidime (85%), Gentamicin (80%), and Colistin (77.5%), while Piperacillin-Tazobactam had a lower resistance rate of 33.3%.The present study highlights the increasing AMR among GNB causing pneumonia in ICU settings post COVID-19 pandemic in hospitals in Northern Iran. The prevalence of Pseudomonas aeruginosa and high resistance rates to new antibiotics such as Colistin pose significant challenges to treatment, while Piperacillin-Tazobactam shows relatively lower resistance and may be a potential option.ConclusionsThe present study highlights the increasing AMR among GNB causing pneumonia in ICU settings post COVID-19 pandemic in hospitals in Northern Iran. The prevalence of Pseudomonas aeruginosa and high resistance rates to new antibiotics such as Colistin pose significant challenges to treatment, while Piperacillin-Tazobactam shows relatively lower resistance and may be a potential option.
Background:The irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked to an increasing burden of healthcare-associated infections caused by multidrug-resistant pathogens, which present substantial challenges for infection control and patient management. During the COVID-19 pandemic, the widespread use of antibiotics for treating and preventing secondary bacterial infections further exacerbated the threat of AMR worldwide. This study aimed to determine the antibiotic resistance profile of Gram-negative bacteria (GNB) causing pneumonia after COVID-19 in Northern Iran.Materials and Methods:In this cross-sectional study, respiratory specimens were collected from hospitalized patients with bacterial pneumonia at four hospitals in Northern Iran. The antimicrobial susceptibility profiles were assessed using the standard microdilution method in accordance with CLSI guidelines (2020). Additionally, resistance-associated genetic determinants were evaluated using multiplex PCR.Results:A total of 120 MDR GNB isolates were identified, primarily from sputum specimens (75.8%). Pseudomonas aeruginosa was the most common pathogen in the ICU, representing 35% of isolates. Resistance rates to antibiotics were high: Ciprofloxacin (85%), Ceftazidime (85%), Gentamicin (80%), and Colistin (77.5%), while Piperacillin-Tazobactam had a lower resistance rate of 33.3%.Conclusions:The present study highlights the increasing AMR among GNB causing pneumonia in ICU settings post COVID-19 pandemic in hospitals in Northern Iran. The prevalence of Pseudomonas aeruginosa and high resistance rates to new antibiotics such as Colistin pose significant challenges to treatment, while Piperacillin-Tazobactam shows relatively lower resistance and may be a potential option.
The irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked to an increasing burden of healthcare-associated infections caused by multidrug-resistant pathogens, which present substantial challenges for infection control and patient management. During the COVID-19 pandemic, the widespread use of antibiotics for treating and preventing secondary bacterial infections further exacerbated the threat of AMR worldwide. This study aimed to determine the antibiotic resistance profile of Gram-negative bacteria (GNB) causing pneumonia after COVID-19 in Northern Iran. In this cross-sectional study, respiratory specimens were collected from hospitalized patients with bacterial pneumonia at four hospitals in Northern Iran. The antimicrobial susceptibility profiles were assessed using the standard microdilution method in accordance with CLSI guidelines (2020). Additionally, resistance-associated genetic determinants were evaluated using multiplex PCR. A total of 120 MDR GNB isolates were identified, primarily from sputum specimens (75.8%). was the most common pathogen in the ICU, representing 35% of isolates. Resistance rates to antibiotics were high: Ciprofloxacin (85%), Ceftazidime (85%), Gentamicin (80%), and Colistin (77.5%), while Piperacillin-Tazobactam had a lower resistance rate of 33.3%. The present study highlights the increasing AMR among GNB causing pneumonia in ICU settings post COVID-19 pandemic in hospitals in Northern Iran. The prevalence of and high resistance rates to new antibiotics such as Colistin pose significant challenges to treatment, while Piperacillin-Tazobactam shows relatively lower resistance and may be a potential option.
Background: The irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked to an increasing burden of healthcare-associated infections caused by multidrug-resistant pathogens, which present substantial challenges for infection control and patient management. During the COVID-19 pandemic, the widespread use of antibiotics for treating and preventing secondary bacterial infections further exacerbated the threat of AMR worldwide. This study aimed to determine the antibiotic resistance profile of Gram-negative bacteria (GNB) causing pneumonia after COVID-19 in Northern Iran. Materials and Methods: In this cross-sectional study, respiratory specimens were collected from hospitalized patients with bacterial pneumonia at four hospitals in Northern Iran. The antimicrobial susceptibility profiles were assessed using the standard microdilution method in accordance with CLSI guidelines (2020). Additionally, resistance-associated genetic determinants were evaluated using multiplex PCR. Results: A total of 120 MDR GNB isolates were identified, primarily from sputum specimens (75.8%). Pseudomonas aeruginosa was the most common pathogen in the ICU, representing 35% of isolates. Resistance rates to antibiotics were high: Ciprofloxacin (85%), Ceftazidime (85%), Gentamicin (80%), and Colistin (77.5%), while Piperacillin-Tazobactam had a lower resistance rate of 33.3%. Conclusions: The present study highlights the increasing AMR among GNB causing pneumonia in ICU settings post COVID-19 pandemic in hospitals in Northern Iran. The prevalence of Pseudomonas aeruginosa and high resistance rates to new antibiotics such as Colistin pose significant challenges to treatment, while Piperacillin-Tazobactam shows relatively lower resistance and may be a potential option. Keywords: Bacterial pneumonia, COVID-19, Gram-negative, multidrug resistance, multiplex polymerase chain reaction
Audience Academic
Author Askari, Mahdieh
Rezai, Shaghayegh
Rezai, Mohammad Sadegh
Rahimzadeh, Golnar
Rezai, Raha
Moradi, Masoud
Author_xml – sequence: 1
  givenname: Golnar
  surname: Rahimzadeh
  fullname: Rahimzadeh, Golnar
– sequence: 2
  givenname: Mahdieh
  surname: Askari
  fullname: Askari, Mahdieh
– sequence: 3
  givenname: Raha
  surname: Rezai
  fullname: Rezai, Raha
– sequence: 4
  givenname: Shaghayegh
  surname: Rezai
  fullname: Rezai, Shaghayegh
– sequence: 5
  givenname: Mohammad Sadegh
  surname: Rezai
  fullname: Rezai, Mohammad Sadegh
– sequence: 6
  givenname: Masoud
  surname: Moradi
  fullname: Moradi, Masoud
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40958933$$D View this record in MEDLINE/PubMed
BookMark eNp1kktv1DAUhSNUREvpliWKxAYWGeJXEktshgHKSFVblcfWunFuBk8Tu7UTBv49Tl_DIHBkObr5zrk31nma7FlnMUmek3zGSc7eQO1ncStaUEXFo-SA0rLMJCnF3h_v-8lRCOs8rqLihZBPkn2eS1FJxg6S9dwOpjfau9pAl15gMGEAqzE1Nj320GenuILB_MD0HegB_USdWxx7Zw2k8zaW0uE7pouzb8v3GZHpOdgGo-NkcOp8_OZtuvRgnyWPW-gCHt2dh8nXjx--LD5lJ2fHy8X8JNOC5z7TWrK2LQgTvGayFRXVvOL5VAbIG14T2SDHAoWuG1qCoKzJdYM5cEKqqmGHyfLWt3GwVlfe9OB_KQdG3RScXynwg9EdKoKxR1nqskXNpSiqsqqFLDSPpgACo9erW68r765HDIPqTdDYdWDRjUExKgiPsxZFRF_-ha7d6G3800hxTgWlstxSK4j9jW3d4EFPpmpeCSaKkomJmv2Dis_NzcYQtCbWdwSvdwSRGfDnsIIxBLX8fLHLvrgbdKx7bB5u6D4U2-4xFSF4bB8QkqspeGoK3TZ4UfD2VrBxXcxDuOzGDXoVzS-t2_xHpe6Tx34DE8DdDg
Cites_doi 10.1093/cid/ciw353
10.1183/09059180.00010302
10.1097/CCM.0000000000000510
10.1007/s10238-022-00959-1
10.1001/jama.290.19.2588
10.5812/jjm.14377
10.1016/S2666-5247(22)00355-X
10.1093/ofid/ofy347
10.1017/ice.2016.174
10.1017/ice.2015.167
10.4103/abr.abr_434_22
10.1016/S1473-3099(20)30731-3
10.1055/s-0041-1741438
10.1186/s13756-016-0143-2
10.1164/ajrccm.165.7.2105078
10.4103/abr.abr_499_24
10.1378/chest.119.2_suppl.373S
10.1164/rccm.200405-644ST
10.32598/jpr.12.3.369.6
10.1056/NEJMoa2004500
10.1155/2015/309478
ContentType Journal Article
Copyright 2025 Advanced Biomedical Research
Copyright: © 2025 Advanced Biomedical Research.
COPYRIGHT 2025 Medknow Publications and Media Pvt. Ltd.
2025. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2025 Advanced Biomedical Research
– notice: Copyright: © 2025 Advanced Biomedical Research.
– notice: COPYRIGHT 2025 Medknow Publications and Media Pvt. Ltd.
– notice: 2025. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID AAYXX
CITATION
NPM
ISR
K9.
7X8
DOA
DOI 10.4103/abr.abr_262_25
DatabaseName CrossRef
PubMed
Gale In Context: Science
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DOAJ - Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
ProQuest Health & Medical Complete (Alumni)

PubMed


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2277-9175
Edition 2
EndPage 92
ExternalDocumentID oai_doaj_org_article_1e4b377c7fec4956878b596c4523aa5e
A853567357
40958933
10_4103_abr_abr_262_25
ABRES-14-92
Genre Journal Article
GeographicLocations Iran
Mississippi
GeographicLocations_xml – name: Mississippi
– name: Iran
GroupedDBID 5VS
7X7
8FE
8FG
8FH
8FI
AAKDD
ABJCF
ABUWG
ACGFS
ACIWK
ACPRK
ADBBV
ADRAZ
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
DIK
EMOBN
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HYE
IAO
IHR
ISR
ITC
KQ8
L6V
LK8
M48
M7P
M7S
M~E
OK1
OVD
PGMZT
PIMPY
PROAC
RMW
RNS
RPM
TEORI
UKHRP
W3E
8FJ
AAYXX
CCPQU
CITATION
H13
HMCUK
IPNFZ
PHGZM
PHGZT
PQGLB
PTHSS
PUEGO
RIG
NPM
K9.
7X8
ID FETCH-LOGICAL-c540r-cc93ff61354b39f582c4840cc93aa0d4b19de4e6e5cbd27a523d0cde0a41188d3
IEDL.DBID W3E
ISSN 2277-9175
IngestDate Mon Sep 08 19:52:08 EDT 2025
Thu Sep 18 00:40:07 EDT 2025
Fri Aug 29 16:32:28 EDT 2025
Thu Sep 11 00:04:45 EDT 2025
Tue Sep 02 03:58:31 EDT 2025
Fri Aug 29 03:31:27 EDT 2025
Sat Sep 20 02:13:09 EDT 2025
Wed Sep 03 16:43:20 EDT 2025
Thu Sep 11 06:18:42 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords COVID-19
multidrug resistance
multiplex polymerase chain reaction
Bacterial pneumonia
Gram-negative
Language English
License Copyright: © 2025 Advanced Biomedical Research.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540r-cc93ff61354b39f582c4840cc93aa0d4b19de4e6e5cbd27a523d0cde0a41188d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doi.org/10.4103/abr.abr_262_25
PMID 40958933
PQID 3244252297
PQPubID 2035645
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_1e4b377c7fec4956878b596c4523aa5e
proquest_miscellaneous_3251461366
proquest_journals_3244252297
gale_infotracmisc_A853567357
gale_infotracacademiconefile_A853567357
gale_incontextgauss_ISR_A853567357
pubmed_primary_40958933
crossref_primary_10_4103_abr_abr_262_25
wolterskluwer_medknow_10_4103_abr_abr_262_25_Antimicr
PublicationCentury 2000
PublicationDate 2025-08-01
PublicationDateYYYYMMDD 2025-08-01
PublicationDate_xml – month: 08
  year: 2025
  text: 2025-08-01
  day: 01
PublicationDecade 2020
PublicationPlace India
PublicationPlace_xml – name: India
– name: Mumbai
PublicationTitle Advanced biomedical research
PublicationTitleAlternate Adv Biomed Res
PublicationYear 2025
Publisher Wolters Kluwer - Medknow
Medknow Publications and Media Pvt. Ltd
Medknow Publications & Media Pvt. Ltd
Wolters Kluwer Medknow Publications
Publisher_xml – name: Wolters Kluwer - Medknow
– name: Medknow Publications and Media Pvt. Ltd
– name: Medknow Publications & Media Pvt. Ltd
– name: Wolters Kluwer Medknow Publications
References (R4-20250829) 2005; 171
Chastre (R5-20250829) 2002; 165
Nadi (R6-20250829) 2011; 29
Rezai (R21-20250829) 2015; 2015
Rahimzadeh (R3-20250829) 2024; 16
Langford (R18-20250829) 2023; 4
Bhatraju (R1-20250829) 2020; 382
Wunderink (R24-20250829) 2021; 21
Chastre (R9-20250829) 2003; 290
Rezai (R22-20250829) 2017; 10
Lynch (R25-20250829) 2001; 119
Kollef (R17-20250829) 2014; 42
Boorgula (R27-20250829) 2022; 14
Rahimzadeh (R13-20250829) 2024; 16
Bagheri-Nesami (R23-20250829) 2016; 5
Rello (R10-20250829) 2007; 16
Rahimzadeh (R8-20250829) 2024; 13
Saberi (R7-20250829) 2011; 16
Rahimzadeh (R11-20250829) 2023; 12
Hosseinzadeh (R2-20250829) 2024; 12
Micek (R16-20250829) 2015; 36
Kalil (R15-20250829) 2016; 63
Castanheira (R26-20250829) 2019; 6
Weiner (R14-20250829) 2016; 37
Murgia (R20-20250829) 2023; 23
Rahimzadeh (R12-20250829) 2022; 40
References_xml – volume: 63
  start-page: e61
  year: 2016
  ident: R15-20250829
  article-title: Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciw353
– volume: 16
  start-page: 33
  year: 2007
  ident: R10-20250829
  article-title: Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia
  publication-title: Eur Respir Rev
  doi: 10.1183/09059180.00010302
– volume: 16
  start-page: 314
  year: 2024
  ident: R13-20250829
  article-title: Evaluation of antibiotic resistance changes in Acinetobacter baumannii in the era of COVID-19 in Northern Iran
  publication-title: Iran J Microbiol
– volume: 29
  start-page: 1161
  year: 2011
  ident: R6-20250829
  article-title: Frequency of nosocomial pneumonia in ICUs of hospitals of Hamadan University of Medical Sciences
  publication-title: J Isfahan Med Sch
– volume: 42
  start-page: 2178
  year: 2014
  ident: R17-20250829
  article-title: Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0000000000000510
– volume: 23
  start-page: 1251
  year: 2023
  ident: R20-20250829
  article-title: The impact of the secondary infections in ICU patients affected by COVID-19 during three different phases of the SARS-CoV-2 pandemic
  publication-title: Clin Exp Med
  doi: 10.1007/s10238-022-00959-1
– volume: 290
  start-page: 2588
  year: 2003
  ident: R9-20250829
  article-title: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults
  publication-title: JAMA
  doi: 10.1001/jama.290.19.2588
– volume: 10
  start-page: e14377
  year: 2017
  ident: R22-20250829
  article-title: Emergence of extensively drug-resistant Acinetobacter baumannii-encoding integrons and extended-spectrum beta-lactamase genes isolated from ventilator-associated pneumonia patients
  publication-title: Jundishapur J Microbiol
  doi: 10.5812/jjm.14377
– volume: 4
  start-page: e179
  year: 2023
  ident: R18-20250829
  article-title: Antimicrobial resistance in patients with COVID-19: A systematic review and meta-analysis
  publication-title: Lancet Microbe
  doi: 10.1016/S2666-5247(22)00355-X
– volume: 6
  start-page: S23
  issue: Suppl 1
  year: 2019
  ident: R26-20250829
  article-title: Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program
  publication-title: Open Forum Infect Dis
  doi: 10.1093/ofid/ofy347
– volume: 16
  start-page: 745
  year: 2024
  ident: R3-20250829
  article-title: High prevalence of antimicrobial resistance genes in multidrug-resistant-ESBLs-producing Klebsiella pneumoniae post-COVID-19 pandemic
  publication-title: Iran J Microbiol
– volume: 37
  start-page: 1288
  year: 2016
  ident: R14-20250829
  article-title: Antimicrobial-Resistant pathogens associated with healthcare-associated infections: Summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011–2014
  publication-title: Infect Control Hosp Epidemiol
  doi: 10.1017/ice.2016.174
– volume: 16
  start-page: 560
  year: 2011
  ident: R7-20250829
  article-title: Frequency of risk factors of ventilator-associated pneumonia in intensive care units of Shahid Beheshti Hospital in Kashan, 2009–2010
  publication-title: Feiz
– volume: 36
  start-page: 1190
  year: 2015
  ident: R16-20250829
  article-title: Pseudomonas aeruginosa nosocomial pneumonia: Impact of pneumonia classification
  publication-title: Infect Control Hosp Epidemiol
  doi: 10.1017/ice.2015.167
– volume: 12
  start-page: 56
  year: 2023
  ident: R11-20250829
  article-title: Genotypic patterns of multidrug-resistant acinetobacter baumannii: A systematic review
  publication-title: Adv Biomed Res
  doi: 10.4103/abr.abr_434_22
– volume: 21
  start-page: 213
  year: 2021
  ident: R24-20250829
  article-title: Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(20)30731-3
– volume: 14
  start-page: 260
  year: 2022
  ident: R27-20250829
  article-title: An update on secondary bacterial and fungal infections and their antimicrobial resistance pattern (AMR) in COVID-19 confirmed patients
  publication-title: J Lab Physicians
  doi: 10.1055/s-0041-1741438
– volume: 5
  start-page: 52
  year: 2016
  ident: R23-20250829
  article-title: Assessment of extended-spectrum β-lactamases and integrons among Enterobacteriaceae in device-associated infections: Multicenter study in north of Iran
  publication-title: Antimicrob Resist Infect Control
  doi: 10.1186/s13756-016-0143-2
– volume: 165
  start-page: 867
  year: 2002
  ident: R5-20250829
  article-title: Ventilator-associated pneumonia
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/ajrccm.165.7.2105078
– volume: 13
  start-page: 123
  year: 2024
  ident: R8-20250829
  article-title: Updating the antimicrobial resistance pattern among critical priority pathogens in the intensive care unit in Northern Iran post COVID-19 pandemic
  publication-title: Adv Biomed Res
  doi: 10.4103/abr.abr_499_24
– volume: 40
  start-page: 743
  year: 2022
  ident: R12-20250829
  article-title: Detection extended-spectrum beta-lactamase-and carbapenemase-producing enterobacteriaceae isolates from clinical samples; Narrative review
  publication-title: J Isfahan Med Sch
– volume: 119
  start-page: 373S
  issue: 2 Suppl
  year: 2001
  ident: R25-20250829
  article-title: Hospital-acquired pneumonia: Risk factors, microbiology, and treatment
  publication-title: Chest
  doi: 10.1378/chest.119.2_suppl.373S
– volume: 171
  start-page: 388
  year: 2005
  ident: R4-20250829
  article-title: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.200405-644ST
– volume: 12
  start-page: 273
  year: 2024
  ident: R2-20250829
  article-title: The Emergence of Multi-Drug-Resistant (MDR) and Extensively-Drug-Resistant (XDR) Pseudomonas Aeruginosa in the COVID-19 Era
  publication-title: J Pediatr Rev
  doi: 10.32598/jpr.12.3.369.6
– volume: 382
  start-page: 2012
  year: 2020
  ident: R1-20250829
  article-title: Covid-19 in Critically Ill patients in the seattle region-case series
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2004500
– volume: 2015
  start-page: 309478
  year: 2015
  ident: R21-20250829
  article-title: Characterization of multidrug resistant extended-spectrum beta-lactamase-producing escherichia coli among uropathogens of pediatrics in North of Iran
  publication-title: Biomed Res Int
  doi: 10.1155/2015/309478
SSID ssj0000684659
Score 2.3025317
Snippet Background: The irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked...
The irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked to an...
Background: The irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked...
Background:The irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked...
SourceID doaj
proquest
gale
pubmed
crossref
wolterskluwer
SourceType Open Website
Aggregation Database
Index Database
Publisher
StartPage 92
SubjectTerms Antibacterial agents
Antibiotic resistance
Antibiotics
Antimicrobial agents
Antimicrobial resistance
Bacteria
Bacterial infections
Bacterial pneumonia
Ceftaroline
Ceftazidime
Ciprofloxacin
Colistin
COVID-19
Drug resistance
Drug resistance in microorganisms
Gentamicin
gram-negative
Gram-negative bacteria
Health aspects
High resistance
Hospital patients
Hospitals
Infection control
Iran
Medical care
Mississippi
Multidrug resistance
Multidrug resistant organisms
multiplex polymerase chain reaction
Original Article
Pandemics
Pathogens
Patients
Piperacillin-tazobactam
Pneumonia
Pseudomonas aeruginosa
Quality management
Sputum
Sulbactam
SummonAdditionalLinks – databaseName: DOAJ - Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQDwgJId4ECjIIiVNo4kcSH7eF0kVqqQpFvVm2M64WtFmU7Iq_z0ySXXaFEBcOucSTKJkZe76JJ98w9hqE9hhIfCpF8KkywaWVq0IqXRZx0SxMBPrecXpWnFyqj1f6aqvVF9WEDfTAg-IOclBelmUoIwQC81VZeW2KoDCDck4Drb6ZybaSqWENxriqzcDSqPJMHjjfvsXDikJY6ou9FYV6sv4_l-StmHT754L2rrvvfen6VgA6vsvujMiRT4YnvsduQHOf3Twd98YfsG-TZjmbz3piJZS7gI6gIdqUzxr-oXXz9Ayue5pvfjhQNKPUeQMrdMSZ4xNqFs4RDvKjT1-n79Lc8HP6wIx3pBv0-zvQNnyKwe0huzx-_-XoJB07KaQBEVmbhmBkjBi5NSrTRF2JoDCzo9POZbXyualBQQE6-FqUDnVbZ6GGzClMQKpaPmJ7zaKBJ4zHMlZ5zOugTa2qGhGFF1JCFFA5YVSWsDdrzdofA2GGxUSDbGBJ_79tkLBDUvxGioiu-xNofjua3_7L_Al7RWazRGXRUK3MtVt1nZ1-vrATRCK6KKUu8ZlGobhYti648dcDfCNiv9qR3N-RxLkWdofX3mHHud5ZhKS48AlhcPjlZpiupPq1BhYrktHUQF0WRcIeD161eW_MsDWiRpkwveNmdj78EPkX9dm1Vz39H3p8xm4J6mzclzbus71lu4LnCLeW_kU_s34BnUsnvQ
  priority: 102
  providerName: Directory of Open Access Journals
Title Antimicrobial Resistance in Gram-Negative Bacterial Pneumonia After the COVID-19 Pandemic in Northern Iran
URI https://doi.org/10.4103/abr.abr_262_25
https://www.ncbi.nlm.nih.gov/pubmed/40958933
https://www.proquest.com/docview/3244252297
https://www.proquest.com/docview/3251461366
https://doaj.org/article/1e4b377c7fec4956878b596c4523aa5e
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfYkBASQnwTGFVASDwFEn8k9mM36FakjWkw2JtlO_ZUpqZT0op_n7sk7RoBLzzkJT5Hju_s-519_pmQt54KC47EJow6m3DlTCKNdAkzaYBJM1fB43rH8Ul-dM4_X4iLPkEWz8Js7d_zLGUfjK3fw6NpTjUVO-Q2LTKF1vuD3aylpDl4UaE6Tsa_VBv4nJaa_88JeMsD3fu1wJ3q5qpNVN9yN5MH5H6PE-Nxp9iH5JavHpE7x_1O-GPyc1wtZ_NZS6MEcme-QSAIGoxnVXxYm3ly4i9bUu94vyNkBqnTyq_A7GYmHuPV4DGAv_jgy_fpxyRT8SkuJ8MX8QPtbo6vq3gKruwJOZ98-nZwlPT3JiQO8FedOKdYCOCnBbdMBSGp4xDH4Wtj0pLbTJWe-9wLZ0taGIhFy9SVPjUcwg1Zsqdkt1pU_jmJQxFkFrLSCVVyWQJ-sJQxH6iXhiqeRuTdumf1dUePoSGsQB1o7P8bHURkHzt-I4W01u0L0LbuR4nOPLS4KFwRvMPITRbSCpU7Dk00RviIvEG1aSSuqDAz5tKsmkZPv57pMeAOkRdMFNCmXigslrVxpj9oAH-EXFcDyb2BJIwsNyxeW4fuR3ajAYDCNEepguLXm2KsidlqlV-sUEbgdekszyPyrLOqzX9DPC0AI7KIiIGZ6Xl3_PEf3afXVvXiP-u9JHcpXl3c5i7ukd1lvfKvAE8t7YjsyMnhqF2NGLUD6zeEMCBN
linkProvider Wolters Kluwer Health
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antimicrobial+Resistance+in+Gram-Negative+Bacterial+Pneumonia+After+the+COVID-19+Pandemic+in+Northern+Iran&rft.jtitle=Advanced+biomedical+research&rft.au=Rahimzadeh%2C+Golnar&rft.au=Askari%2C+Mahdieh&rft.au=Rezai%2C+Raha&rft.au=Rezai%2C+Shaghayegh&rft.date=2025-08-01&rft.issn=2277-9175&rft.eissn=2277-9175&rft.volume=14&rft.spage=92&rft_id=info:doi/10.4103%2Fabr.abr_262_25&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2277-9175&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2277-9175&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2277-9175&client=summon